Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (502)	10/3/2010 1:30:43 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 566

that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones Thanks. 25 million into the bank and, ......... AstraZeneca is responsible for all development, regulatory filings, manufacturing and global commercialization activities in all licensed indications under the contract. ........ In my thinking Rigel should have a balance sheet of over 200 million. 187 at end of second qtr. and some millions left from the original payment from AZ and this new 25 million payment. Last qtr expenses were 22.5.